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ttp://dx.doi.org/10.1016/j.ajpath.2013.08.018DNAmethylation is one of themost important epigenetic mechanisms in regulating gene expression. Genome
hypermethylation has been proposed as a critical mechanism in human malignancies. However, whole-
genome quantiﬁcation of DNA methylation of human malignancies has rarely been investigated, and the
signiﬁcance of the genome distribution of CpG methylation is unclear. We performed whole-genome
methylation sequencing to investigate the methylation proﬁles of 13 prostate samples: 5 prostate cancers, 4
matched benign prostate tissues adjacent to tumor, and 4 age-matched organ-donor prostate tissues. Al-
terations of methylation patterns occurred in prostate cancer and in benign prostate tissues adjacent to
tumor, in comparison with age-matched organ-donor prostates. More than 95% alterations of genome
methylationoccurred in sequences outside CpG islands.Only a small fractionof themethylatedCpG islandshad
any effect on RNA expression. Both intragene and promoter CpG islandmethylations negatively affected gene
expression. However, suppressions of RNA expression did not correlate with levels of CpG islandmethylation,
suggesting that CpG island methylation alone might not be sufﬁcient to shut down gene expression. Motif
analysis revealed a consensus sequence containing Sp1 binding motif signiﬁcantly enriched in the effective
CpG islands. (Am J Pathol 2013, 183: 1960e1970; http://dx.doi.org/10.1016/j.ajpath.2013.08.018)Supported by NIH grant R01-CA098249 (J.H.L.), American Cancer
Society grant RSG-08-137-01-CNE (Y.P.Y.), and a grant from the Uni-
versity of Pittsburgh Cancer Institute.
Y.P.Y. and Y.D. contributed equally to this work.
Y.P.Y., G.C.T., and J.-H.L. contributed equally to this work as senior
authors.Prostate cancer is one of the most prevalent malignancies
among American men. Approximately 241,740 new cases
and up to 28,170 prostate cancer deaths were estimated for
the United States in 2012.1 The mortality rate from prostate
cancer is second only to lung carcinoma in the United
States.1 Although most prostate cancers are indolent and
responsive to the available surgery and radiation in-
terventions, a signiﬁcant number of cases become hormone
refractory and metastatic. The precise mechanism of pros-
tate cancer progression remains elusive, despite extensive
research efforts and recent advances in understanding of this
disease. Comprehensive gene expression and genome ana-
lyses have suggested that a global pattern of gene expression
and copy number alterations exist for prostate cancer.2e7
The related gene products include critical molecules in
signaling pathways, DNA replication, cell growth, cell-
cycle checkpoints, and apoptosis.2,8e10
Hypermethylation of a gene promoter region is a critical
epigenetic event that silences gene expression and playsstigative Pathology.
.important roles in normal physiology. Genome allele methyl-
ation mediates gene imprinting for inactivation of the X chro-
mosome11 and generates tissue-speciﬁc gene expression.12 In
pathological processes, DNA methylation inactivates tumor
suppressor genes and promotes tumorigenesis.13,14 Genome
hypermethylation has been proposed as a criticalmechanism in
human malignancies.13e18 Silencing of genes involved in cell-
cycle control, cell survival, DNA damage repair, and signal
transduction is a characteristic of cancer cells.19e27 However,
there is a lack of global quantiﬁcation of CpG dinucleotide
methylation and gene expression in prostate cancer. To map
whole-genome CpG dinucleotide methylation leading to
altered expression of hundreds of genes in prostate cancer, we
Prostate Cancer Methylation Sequencingperformed whole-genome methylation sequencing and char-
acterized the methylation proﬁles in a set of prostate tumors,
matched benign prostate tissues adjacent to tumor, and age-
matched organ-donor prostate tissues. Unique methylation
proﬁles distinguished the three types of samples.
Materials and Methods
Sample Preparation and Genomic DNA Extraction
Frozen specimens of prostate tumor (T) (n Z 5), matched
benign prostate tissues adjacent to tumor (AT) (nZ 4), and
organ-donor prostate tissues (OD) (n Z 4) were obtained
from the Tissue Bank of the University of Pittsburgh as
approved by the Institutional Review Board. Clinicodemo-
graphic characteristics for the tumor specimens are listed in
Table 1. Each sample was microdissected to achieve >80%
purity of cancer cells or prostate epithelial cells. AT samples
(>3 mm away from the cancer) were obtained using needle
microdissection by board-certiﬁed pathologists (J.H.L. and
G.M.). Organ donor samples were from healthy individuals
free of any urological disease. Genomic DNA of each set of
OD, T, and AT tissues was extracted using a commercially
available tissue and blood DNA extraction kit (Qiagen,
Valencia, CA).
Sodium Bisulﬁte Conversion of Genomic DNA and
Generation of Sequencing Library
Genomic DNA was bisulﬁte-converted with an EpiTect
bisulﬁte conversion kit (Qiagen, Valencia, CA). For each
sample, 1 mg of genomic DNA was incubated with sodium
bisulﬁte solution at 60C for 4.5 hours. This was followed by
desulfonation, puriﬁed through the column according to the
manufacturer’s instructions. The complementary strand was
synthesized by incubating bisulﬁte-treated DNA with
random hexamer and dNTP using T4 DNA polymerase and
T4 DNA ligase for 18 hours at 16C. Double-stranded DNA
was then puriﬁed with Agencourt AMPure beads (Beckman
Coulter, Brea, CA). To prepare the genomic DNA libraries,
50 ng DNA was then subjected to the tagmentation reactions
(ie, transposase-based DNA fragmentation and adaptor
ligation) using a Nextera DNA sample preparation kitTable 1 Prostate Cancer Tumor Specimen Characteristics and
Clinical Data
Case TNM Gleason score Age (decade) PSA, pre-operative
49T T3bN1MX 7 50s 14.6
158T T3aN0MX 7 60s 4.1
159T T2cN0MX 8 60s 2.38
165T T3bN1MX 10 50s 29.3
171T T3bN1MX 10 50s 9.17
All ﬁve specimens were relapse tumors from European-origin (white)
patients. Organ donor prostate specimens were from four healthy age-
matched individuals (OD23 and OD25 in their 50s; OD20 and OD22 in
their 60s) free of any urological disease.
The American Journal of Pathology - ajp.amjpathol.org(EpicentreeIllumina, Madison, WI) for 5 minutes at 55C.
The DNA was then ampliﬁed with adaptor and sequencing
primers for nine cycles of 95C for 10 seconds, 62C for 30
seconds, and 72C for 3 minutes. The PCR products were
puriﬁed with AMPure beads. The bisulﬁte-converted
genomic DNA libraries were then analyzed with qPCR
using Illumina (San Diego, CA) sequencing primers and
visualized with an Agilent 2000 bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA) or agarose gel electrophoresis.
Whole-Genome Sequencing
The Illumina whole-genome sequencing systemwas applied to
the analysis. The operation procedures strictly followed the
manufacturer’s instructions. In brief, the bisulﬁte-converted
DNA libraries were hybridized to ﬂow cells and subjected to
primer extension and bridge ampliﬁcation in an automated cBot
process for 4 hours to generate a cluster of DNA sequencing
templates. These clustered ﬂow cells were then subjected to the
sequencing analysis in an Illumina HiSeq 2000 system. Each
library was sequenced with an average 27-fold genome
coverage and with paired-end runs for 200-cycle analysis.
Read Alignment and b-Value Calculation for Bisulﬁte
Sequencing
We used Bismark software28 version 0.6.3 to align paired-
end bisulﬁte-treated DNA reads against the UCSC human
reference genome build hg19 (http://genome.ucsc.edu, last
accessed April 14, 2013). Bismark generated the BS-seq
reference from build hg19 containing C-to-T conversion for
the forward strand and G-to-A conversion for the reverse
strand. Sequencing batches with more than 7% non-CpG un-
converted cytosine were excluded from further analysis.
Uniquely best-mapped reads were pooled with at most two
mismatches and fragment size of mate pairs ranging from 400
to 1400 bp. Themethylation extractor tool inBismark called all
cytosine methylation status of each CG. After methylation
calling, we characterized themethylation strength of eachCpG
island and of 200-bp moving windows of the human whole
genome in termsof thebvalue, calculated asbZTotal number
ofmethylated calls in region/(Total number ofmethylated calls
in regionþ Total number of unmethylated calls in region).
Read Alignment and Estimation of Expression Value for
RNA-Seq
RNA-seq reads were at an average 1000 coverage. Whole-
genome RNA-seq reads were aligned with TopHat soft-
ware29,30 version 1.4.1 against the UCSC reference genome
build hg19, allowing two mismatches per any 100-bp read.
TopHat used uniquely mapped reads (against the reference
genome) and the genomic database (UCSC hg19 Gene
Annotation) to build up a potential splicing sites database.
Borrowing information from potential splicing sites, iso-
forms were determined. We then used Cufﬂinks software29,311961
Yu et alversion 1.3.0 to calculate the fragments per kilobase of exon
per million fragments mapped (FPKM) to measure the
abundance of the transcripts for pair-end reads and obtained a
gene-based FPKM value that summarized all isoforms in a
given gene.
Window-Based Differential Methylation Analysis
Moving windows (200 bp) on the whole human genome
(build hg19) were used to study methylation differences in
different regions among the different groups (T, AT, and
OD). Fisher’s exact test was used to assess the signiﬁcance of
differential methylation. A moving window was determined
to be differentially methylated if the difference between the
average b value of two groups was >0.4 and the adjusted P
value from Fisher’s exact test (false discovery rate controlled
by BenjaminieHochberg procedure) was <0.01. After
differentially methylated moving windows were identiﬁed,
we used MethylKit software32 version 0.5.6 to characterize
the genomic features of these moving windows. We deﬁned
the CpG shores as the 1000 bp upstream and downstream of a
CpG island and the promoter as the 3000 bp upstream and
500 bp downstream of transcription start site.
CpG Island Differential Methylation Analysis
A redeﬁned CpG island annotation database was applied to
deﬁne our CpG island region.33,34 We classiﬁed the CpG
islands into three types: nonegene-associated, intragene, and
promoter CpG islands. The CpG gene association was
deﬁned as CpG islands located from 3000 bp upstream of an
mRNA start site to the end of the transcript. A promoter CpG
island was deﬁned as a CpG island located between 3000 bp
upstream and 500 bp downstream of the mRNA start site, and
the intragene CpG island was deﬁned as a CpG island located
in the gene-containing genome sequence from 500 bp
downstream of the transcription start site to the end of the last
exon. The intergene CpG island was deﬁned as a CpG island
located in a nongene region at least 3000 bp away from an
mRNA start site. We classiﬁed 66,765 CpG islands into
32,841 intragene, 9454 promoter, and 24,470 intergene CpG
islands. Differentially methylated CpG islands were obtained
for three pairwise comparisons: T versus OD, AT versus OD,
and T versus AT. The signiﬁcance of differential methylation
was assessed by a two-sample t-test based on the b value for
each sample of each speciﬁc CpG island. For each compar-
ison group, the differentially methylated CpG islands were
separated into two groups, hypermethylated and hypo-
methylated, using the AT or OD group as the baseline.
Determination of Functional Effect of CpG Methylation
on RNA Expression
We deﬁned a CpG island as functional if hyper- or hypo-
methylation of a CpG island in one group relative to the
other was associated with signiﬁcantly lower or higher1962average RNA expression. To determine whether the differ-
entially methylated CpG islands were functional, we com-
bined the bisulﬁte-seq data with the RNA-seq data after
matching the genes to the gene-associated CpG islands. We
ﬁrst performed quantile normalization on FPKM values
from RNA-seq data across all samples. The differential
expression of a given gene was determined with a preset
P-value threshold from the t-test on normalized FPKM
values. A differentially hypermethylated CpG island was
determined to be functional if its overlapping gene was
differentially down-regulated based on the RNA-seq data;
conversely, a functional differentially hypomethylated CpG
island was required to show up-regulation of associated gene
expression. The differential expression analysis was per-
formed through paired t-test on normalized FKPM values
obtained from TopHat and Cufﬂinks. A P-value threshold of
0.05 was applied to both differential methylation and dif-
ferential expression calling. This was combined with a re-
quirement of opposite direction of effect size of differential
methylation and differential expression. Six sets of functional
differentially methylated genes were identiﬁed (by collecting
all genes that had at least one functional differentially
methylated CpG island): hyper- and hypomethylated genes in
T versus OD, AT versus OD, and T versus AT comparisons.
TCGA Data Preparation
Data were downloaded from the Cancer Genome Atlas
(TCGA) (http://tcga-data.nci.nih.gov/tcga) in October
2012. Level 3 RNA-seq data were extracted from the Illu-
mina HiSeq 2000eAgilent array platform and methylation
data from an Inﬁnium HumanMethylation450 beadchip kit
(Illumina). We selected four TCGA cancer data sets that
contained methylation and expression data from matched
tumor and normal tissue adjacent to tumor samples: breast
invasive carcinoma (BRCA), prostate adenocarcinoma
(PRAD), head and neck squamous cell carcinoma (HNSC),
and thyroid carcinoma (THCA). The numbers of samples
available for differential methylation and gene expression
integrative analyses are given in Supplemental Table S1.
After gene matching between methylation data and gene
expression data, paired t-tests for each gene were performed
to calculate P values of differential expression and differ-
ential methylation. Because of variable sample sizes in each
of the TCGA studies, the P-value threshold for deﬁning
functional differential methylated genes varied. We varied
the P-value threshold to obtain a functional gene set of
approximately 500 (760 in PRAD, 395 in BRCA, 422 in
HNSC, and 510 in THCA).
Motif Analysis
Paired t-tests for our data set and the four TCGA data sets were
performed for each gene to calculate theP value for differential
expression and differential methylation. Each gene was then
ranked by the P values obtained from the rank-sum tests forajp.amjpathol.org - The American Journal of Pathology
Prostate Cancer Methylation Sequencingdifferential expression and differential methylation. CpG
islands with increase in methylation b values (P < 0.05)
resulting in twofold decreased expression (P < 0.05) of the
overlapping gene were deemed concordant and effective. The
noneffective groups were deﬁned as differential methylation
having weak or no effect on expression (P > 0.5). Motif
enrichment analysis, comparing effective CpG islands versus
noneffective CpG islands, was performed with MEME soft-
ware35 version 4.9.0 using the following criteria: size, 6 to 20
bp; frequency, 0 or 1 per CpG island; and present in >20
effective CpG islands. Effective groups were treated as a
positive data set and noneffective groups as a negative data set.
After obtaining multiple motifs from all data sets, these motifs
were matched with known motifs from the TCGA database
with the TOMTOM motif comparison tool.36 Pearson corre-
lation was set as the similarity measure with a signiﬁcance
threshold of q Z 0.01 in TOMTOM. We then compared re-
sults from our data set and the four TCGA data sets to identify
recurrent motifs enriched in effective CpG islands.
Gene Set Enrichment Analysis
To investigate whether the functional CpG (200-bp moving
window) methylated genes show statistically signiﬁcant
enrichment in certain biological pathways, we used pathways
from Biocarta and KEGG databases curated by Molecular
Signatures Database (MSigDB) (http://www.broadinstitute.
org/gsea/msigdb/index.jsp, last accessed May 3, 2013;
http://www.biocarta.com/genes/index.asp, and http://www.
genome.jp/kegg/pathway.html, last accessed December 12,
2012).37 One-sided Fisher’s exact test (over-representation)
was applied to calculate the statistical signiﬁcance of pathway
enrichment. The P values were corrected by the Benjaminie
Hochberg procedure for multiple comparisons to calculate
q values.
Results
Whole-Genome Methylation Analysis Suggests Partial
Hypomethylation in Prostate Cancer and an
Individualized Field Effect in Benign Tissues Adjacent
to Tumor
To identify alterations of global genome methylation pattern
in prostate cancer, microdissected genomic DNAs from the
13 prostate samples (T, AT, and age-matched OD) were
bisulﬁte-treated and sequenced using Illumina HiSeq 2000,
with an approximate coverage of 8 1010 bp for each sample
and 27-fold per allele. Moving windows of 200-bp width
were used to scan the whole human genome (build hg19) and
to aggregate the methylated and unmethylated calls from
Bismark.28,38 To ensure proper evaluation of methylation b
value, each windowwas screened for a minimal of 50 calls on
methylation status, based on 13 sequencing samples. This
resulted in more than 8.8 million windows for methylation
analysis. The majority (76%) of windows of human genomeThe American Journal of Pathology - ajp.amjpathol.orgsequences appeared to be methylated (b Z 0.5 to 1.0)
(Figure 1A). Genome sequences with high methylation
(average b > 0.9) or without methylation (average b < 0.1)
from OD, AT, and T samples were identiﬁed. More than 1.8
million windows were identiﬁed as highly methylated in T
samples (Figure 1B). In contrast, more than 2.6 million se-
quences were found with high methylation in OD samples.
The AT samples had 2.27 million highly methylated win-
dows. Interestingly, OD tissues also had a larger number of
nonmethylated windows (70,837) (b < 0.1), compared with
T (59,904) (Figure 1B). Approximately 8% (146,452) of
highly methylated windows were unique to the T samples,
but 27% (703,895) were unique to OD tissue. These results
suggest that partial loss of hypermethylation may be an
important epigenomic alteration in prostate cancer.
A total of 216,299 sequence windows were differentially
methylated in T samples, compared with OD (Db > 0.4, q <
0.01) (Figure 1C). Of these sequences, 173,297 (>80%) were
differentially hypomethylated in T samples. In contrast, only
58,290 sequences were differentially methylated between T
and AT samples. More than 93% (54,329) of these sequences
were hypomethylated. Signiﬁcant differential methylation
was also found between AT and OD samples, with 36,839
sequences differentially methylated in AT, of which 31,336
(85.1%) were hypomethylated. Interestingly, only 1% of
these sequences were located in CpG islands, and 2% to 4%
in shore regions. Of these differentially methylated se-
quences, 2% to 4% were located in promoter regions of T
compared with OD, or T compared with AT, or AT compared
with OD (Figure 1D). A majority of the differentially meth-
ylated sequences were located in intergenic regions with no
known function, suggesting that methylation of these se-
quences serves a function unrelated to gene transcription.
To investigate the relatedness of methylation patterns of
these samples, a hierarchical clustering analysis of 13
samples based on b values of a ﬁltered set of windows was
performed. Three main groups of clustering were identiﬁed
(Figure 1E). All four OD samples segregated into a branch,
unrelated to either AT or T; however, three of the four AT
samples clustered with the matched T sample. These results
suggest that methylation in benign prostate adjacent to
tumor is closely related to cancer rather than to normal
prostate tissues, and indicates an individualized ﬁeld effect.
To investigate the effect of methylation on gene expres-
sion, RNA sequencing was performed for each sample.
Differentially methylated sequences (Db > 0.4, q < 0.01)
overlapping with known genes were selected to correlate
with expression suppression of the overlapping genes (>0.5-
fold down-regulation, P < 0.05). Methylations of 10,710
sequence windows (1418 genes) correlated with gene
expression alteration for T versus OD samples, whereas
3591 sequences (828 genes) correlated for T versus AT
samples (Figure 2). Also, 2978 eight sequences (908 genes)
were differentially methylated between AT and OD samples.
Pathway analyses indicated differential methylation asso-
ciation with several important signaling pathways in T1963
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Figure 1 Methylation of human genomes of T, AT, and OD prostate tissue. A: Methylation status of approximately 8.8 million genomic sequences (200-bp
window) of T, AT, and OD. B: Distribution of hypermethylated (b > 0.9) and hypomethylated (b < 0.1) sequences in T, AT, and OD. C: Characteristics of
differentially methylated sequences for T versus OD, T versus AT, and AT versus OD. D: Location distribution of differentially methylated sequences for the same
three comparisons. E: Phylogenetic dendrogram of correlation of methylation b values among the 13 samples. AT, matched benign prostate tissues adjacent to
cancer; OD, organ-donor prostate tissues; T, frozen specimens of prostate cancer.
Yu et alsamples, compared with OD samples, including hyper-
methylation and down-regulation of several tumor suppressor
genes (eg, RXRG, FH, CCDC6, RARA, and GPX3) in the T
samples. In addition, signiﬁcant hypermethylation and down-
regulation of genes in extracellular matrix, adhesion, and
integrin signaling pathways were found in T samples
(Supplemental Table S2), whereas several oncogenes [eg,
NCOA4 (alias PTC3), BIRC2, FGF6, and HGF] were hypo-
methylated and up-regulated (Supplemental Table S3). Sig-
niﬁcant numbers of calcium signaling pathway genes were
down-regulated and hypermethylated in T samples,
compared with AT, whereas the ubiquitin-mediated proteol-
ysis pathway was hypomethylated (Supplemental Tables S4
and S5). These results suggest a critical role of DNA
methylation in prostate cancer. Interestingly, signiﬁcant
demethylation and up-regulation were found in RAS and
MAPK pathways in AT samples, compared with OD
(Supplemental Tables S6 and S7), suggesting a precursor
alteration that may lead to prostate cancer.
CpG Island Methylation Analysis Indicates a Strong
Field Effect of Prostate Cancer
CpG island methylation is widely credited for gene
expression suppression. Our CpG island methylation-1964sequencing analyses showed that 34,493 to 36,530 of
66,765 (51.7% to 54.7%) CpG islands had at least one allele
methylated across all samples. There was no signiﬁcant
statistical difference in the total number of CpG islands
methylated among the different groups. Approximately 40%
of the CpG islands had both alleles methylated (b > 0.8) in
all three groups, with little variation among samples
(Figure 3A and Supplemental Figure S1). When the CpG
islands were categorized into promoter, intragene, and
intergene CpG islands, 53.4% of the intragene CpG islands
and 63.9% of the intergene islands were methylated in at
least one allele. In contrast, only 16.2% of the CpG islands
in the promoter region were methylated (Figure 3, BeD).
When samples were segregated into OD, AT, and T types, a
signiﬁcant increase in one-allele CpG island methylation
(b Z 0.5 to 0.8) in T versus OD (P Z 0.04) was found,
whereas there was no signiﬁcant difference between two-
allele methylation (b > 0.8) across all groups. The fre-
quencies of one-allele methylation of the intergene (P Z
0.017) and promoter CpG (P Z 0.0017) CPG islands were
increased in the T samples, compared with the age-matched
OD samples. Interestingly, similar differential methylations
were also found in the AT versus OD comparison for either
intergene (P Z 0.031) or promoter (P Z 0.026), albeit in
lower frequencies.ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Differential methylation of gene-associated differentially methylated sequences among T, AT, and OD tissues. Differential methylation of a
sequence (200-bp window) is deﬁned as a >0.5 difference in average b value, with q < 0.01, between T and OD, T and AT, or AT and OD.
Prostate Cancer Methylation SequencingTo investigate whether speciﬁc gene-associated CpG
methylations are associated with the development of pros-
tate cancer, intragene and promoter CpG islands in the T
samples were screened for a >0.2 difference in average b
value (P < 0.05), compared with the corresponding CpG
islands in the OD samples. The screening identiﬁed 2258
gene-associated CpG islands hypermethylated in T samples,
relative to OD samples (Figure 4). Only 343 CpG islands
had reduced methylation in T samples. Relative to the AT
samples, however, only 41 CpG islands (12 promoters and
29 intragenes) were hypermethylated in the T samples,
whereas 76 had reduced methylation. In contrast, 1035
gene-associated CpG islands were hypermethylated in the
AT samples, relative to the OD samples; 774 (75%) of these
CpG islands overlapped with those in the T samples, and 70
had reduced methylation. These results suggest that signif-
icant alterations in methylation patterns occur in prostate
tissues adjacent to tumor and that these alterations are quite
similar to those in prostate cancer.A Small Fraction of Methylated CpG Islands Correlates
with Gene Expression Suppression
To evaluate the effect of CpG island methylation on gene
expression, the top and bottom quantile of expressed genes
were selected to determine the distribution of promoter CpG
island methylation. Approximately 3.5-fold more genes
were methylated in at least one allele (bZ 0.6 to 1.0) in the
promoter in the low-expressing versus top-expressing genes
in T samples (Figure 5). Similar results were also found in
OD and AT samples. To a lesser extent, such results wereThe American Journal of Pathology - ajp.amjpathol.orgalso found in intragene CpG island methylation distribution
(Supplemental Figure S2).
To investigate whether all methylated CpG islands are
functional in suppressing gene expression, differential expres-
sion of genes was determined among the T, AT, andODgroups
according to the criteria of greater than twofold alteration and
P< 0.05. Gene-associated CpG islands were deemed effective
whendifferentially increasedmethylation (P< 0.05) resulted in
down-regulation of mRNA transcripts in matched samples.
Compared with the OD samples, in the T samples only 416/
4901 (8.5%) CpG island methylations were effective in
reducing the transcription of the corresponding genes
(Figure 6A and Supplemental Figure S3). Interestingly, 354
(85%) of these CpG islands were located within the introns or
internal exons of the genes, and only 62 (15%) CpG islands
were located in the promoter/exon 1 regions. With the AT
samples used as baseline values, 100/1172 (8.5%) CpG islands
were determined to be effective in suppressing gene expression
in the T samples. The majority of these CpG islands [88/100
(88%)] were located in intron or internal exon regions, and 12
were considered classical promoter CpG islands. Similar ﬁnd-
ings were obtained in comparison of AT versus OD samples:
184/2512 (7.3%) CpG islands were found to be effective in the
AT samples, and 164 (89%) of these CpG islands were intra-
gene islands. These results suggest that intragene CpG islands
play a critical role in regulating gene expression. To rule out a
data-speciﬁc effect, concordance analyses were performed of
the four TCGA cancer data sets. Less than 15% of CpG island
differential methylation correlated with down-regulation of
RNA expression in these data sets (Supplemental Figure S4).
This largely conﬁrmed our ﬁndings of an extensive presence of
nonfunctional CpG islands in the human genome.1965
Figure 3 Distribution of methylation of CpG islands in OD, T, and AT tissues expressed as the average b value of each CpG island and the average frequency
of one-allele methylation (b Z 0.5 to 0.8) for all CpG islands (A) and for the intragene (B), promoter (C), and intergene (D) categories.
Yu et alTo investigate whether the level of CpG methylation in a
given CpG island correlates with the expression suppression
activity, the differences in CpG island methylation were
correlated with the differences in RNA transcription levels.
Surprisingly, we found poor correlation between the quan-
tity of methylated CpGs and suppression of RNA tran-
scription (Pearson coefﬁcient Z 0.1 to 0.2). The levels of
transcription suppression by intragene or promoter CpG
islands were not signiﬁcantly different (Figure 6B).
Analyzing the length, GC content, and CpG count of the
CpG islands (normalized to CpG island length) and quan-
tifying the levels of CpG methylation in the TATA box
regions yielded largely insigniﬁcant results between effec-
tive and noneffective CpG islands (Supplemental Table S8).
These results suggest that the density of CpG dinucleotide
methylation, the GC contents of CpG islands, and the dis-
tribution of methylated CpGs are not the critical factors in
gene suppression by DNA methylation.
To investigate whether a sequence element in a CpG is-
land contributes to the effectiveness of a CpG island in
suppressing gene transcription when methylated, sequence
motifs enriched in effective CpG islands (differential
methylation and differential expression at P < 0.05) were1966compared with noneffective ones (differential methylation
and differential expression at P > 0.5) using the MEME
motif analysis tool.35 A CCCC[GT]CCCCC motif was
signiﬁcantly enriched in the effective CpG islands. Similar
motif analysis was then applied to the effective intragene T
group, as well as to four TCGA cancer data sets. The top
enriched motifs for each data set were identiﬁed, and sig-
niﬁcant sequence homology among these motifs was found
(Figure 7). Subsequently, these top enriched motifs from
each data set were matched against the curated online
TCGA database using the tool TOMTOM.36 The results
indicate that a sequence motif rich in guanine nucleotides
signiﬁcantly close to a known binding motif for Sp1 was
found in all the data sets except HNSC (Figure 7). The wide
presence of this motif in effective CpG islands suggests a
possible critical role of this sequence in enabling the tran-
scription suppression of methylated CpG islands.
To investigate whether differential methylation of
intergene CpG islands also occurs among the OD, AT, and
T groups, the samples were screened for CpG islands with
a >0.2 difference in methylation b value (P < 0.05).
Relative to OD samples, 1689 intergene CpG islands were
hypermethylated and 341 were hypomethylated in theajp.amjpathol.org - The American Journal of Pathology
Figure 4 Differential methylation of gene-associated CpG islands among T, AT, and OD tissue. Differential methylation is deﬁned as a >0.2 difference of
average b values and P < 0.05 for T versus OD (A), T versus AT (B), or AT versus OD (C).
Prostate Cancer Methylation SequencingT samples (Supplemental Figure S5). Relative to AT
samples, only 43 intergene CpG islands were hyper-
methylated and 71 were hypomethylated in the T samples.
Signiﬁcant differential methylations were also found in the
AT group, relative to the age-matched OD group: 835
hypermethylated and 65 hypomethylated CpG islands. The
functions of these CpG islands have yet to be character-
ized. The differential methylation status of these islands in
our analyses, however, suggests that they may play a role
in carcinogenesis.0.8
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Figure 5 Low-level gene expression is associated with higher frequency
of promoter CpG island hypermethylation. Promoter CpG island methylation
b value distribution of top and bottom quantile of expressed genes in T (A),
AT (B), and OD (C) tissue.Discussion
Whole-genome methylation sequencing is a new and
important tool with which to gain insight into the devel-
opment of cancer. Compared with array-based or methyl-
ation CpG pull-down sequencing, bisulﬁte sequencing
provides a substantial advantage in both resolution and ac-
curacy. First, bisulﬁte whole-genome sequencing de-
termines the methylation status of CpG dinucleotide across
the entire genome and mitochondria DNA, whether within
or outside of a CpG island. Second, bisulﬁte sequencing
quantiﬁes the level of methylation in an accurate manner
such that we can determine minute methylation variation in
any CpG dinucleotide. Because of the highly quantitative
feature, this method enables detection of subtle differences
in methylation between groups. This is unlikely to be ach-
ieved with other methodologies. To our knowledge, the
present study is the ﬁrst application of whole-genome
bisulﬁte sequencing in prostate cancer.The American Journal of Pathology - ajp.amjpathol.orgOur analysis suggests that the majority of hypermethylated
sequences were located outside the boundary of CpG islands.
More than 95% of alterations of CpG methylation in cancer
occur in sequences unrelated to CpG islands. The results of
genomic differential methylation among T, AT, and OD
samples were robust and signiﬁcant when the analysis was
performed using the entire genomic sequence. The numbers
of differential methylation sequences were dramatically
reduced, however, when the analysis was focused only on
CpG islands. These ﬁndings suggest that potential func-
tionally signiﬁcant methylation information lies outside CpG1967
Figure 6 Effect of CpG island methylation on
RNA expression. A: Correlation of CpG island
methylation on RNA expression. Effective CpG
islands of promoter and/or intragene were
screened by the difference at P < 0.05 in b values
between T and OD, A and AT, or AT and OD and RNA
expression with greater than twofold down-
regulation at P < 0.05. B: Concordance of CpG
island differential methylation and suppression of
RNA expression. Differences in methylation levels
(b values) were plotted against differences in RNA
expression (FKPM). Each data point represents an
average value from each CpG island that is deemed
effective in suppressing RNA expression.
Figure 7 Motif enrichment in effective CpG islands. Motif identiﬁcation
using MEME programs among CpG islands with an increase at P < 0.05 of
methylation resulted in greater than twofold decrease of RNA expression at
P < 0.05 in the prostate cancer whole-genome methylation sequencing set
and in the PRAD, BRCA, and THCA data sets from TCGA.
Yu et alislands. Large numbers of differentially methylated se-
quences (both CpG island and non-CpG island) exist in the
intergene regions, suggesting that the function of methylation
of genome sequences probably serves more than just regu-
lation of gene transcription.
A surprising ﬁnding was that more than 90% of differ-
ential CpG island methylations had minimal effect on gene
expression when matched RNA sequencing was performed
to quantify the transcription level. The number of effective
differential CpG island methylations was barely greater than
400 when T samples were compared with ODs. There was a
lack of correlation between the effectiveness of CpG
methylation-mediated suppression and levels of methyl-
ation, size of CpG islands, CpG counts, or TATA box re-
gion methylation. This suggests that CpG island
methylation is probably not the overriding factor in sup-
pressing gene transcription. Our motif analyses suggest a
signiﬁcant enrichment of transcription binding complex in
most of the effective CpG islands in the promoter regions.
Similar sequences were also found enriched in the effective
groups from three of the four TCGA cancer data sets
(PRAD, BRCA, and THCA). All these motif sequences
share the Sp1 binding sites. Thus, transcription factor
binding is implicated for methylation-induced gene tran-
scription suppression. This argument is strengthened by the
ﬁnding that most of the intragene CpG islands effective in
suppressing gene transcription also contain the similar
sequence. Our ﬁndings suggest that the transcription sup-
pression activity of CpG islands is quite independent of the
location relative to the RNA polymerase binding site
(TATA), whether in the promoter or intragene region.
Previous studies have suggested a signiﬁcant ﬁeld effect
of prostate cancer through methylation genome array ana-
lyses.39e42 Our whole-genome methylation sequencing1968analyses afﬁrm a signiﬁcant ﬁeld effect of prostate cancer in
benign tissues adjacent to tumor. This is evidenced by the
close similarity in methylation patterns between the T and
AT tissues in both whole-genome CpG and CpG island
methylation analyses. The numbers of CpG islands differ-
entially methylated between age-matched OD tissues and T
tissues were more than 20-fold higher than between T and
AT tissues, even if these tissues were located in different
quadrants or different sides from the cancers.
The present ﬁndings suggest that epigenomic changes
occur in morphologically nonmalignant cells. These changesajp.amjpathol.org - The American Journal of Pathology
Prostate Cancer Methylation Sequencinglikely form the basis of a cancerous epigenome that propels
the benign tissue to develop into morphological cancer.
Two good examples of OD-to-T transition in methylation
patterns are the LDLRAD2 and FGF2 genes (Supplemental
Figure S3). The effective CpG island of LDLRAD2 is
intronic, whereas the CpG island of FGF2 is in promoter/
exon 1 regions. OD samples had low levels of methylations
in both genes; however, signiﬁcant elevation of methylation
of CpGs was found in AT samples. The highest levels of
methylation were found in T samples. This methylation
negatively affected the expression of these two genes
(Supplemental Figure S3). The signiﬁcant methylation
pattern differences in benign prostate tissues in a prostate
gland containing cancer (the AT group), relative to normal
prostate without cancer (the OD group), have clinical sig-
niﬁcance, because a ﬁnding of such a pattern signiﬁes the
presence of prostate cancer in a nearby location. Indeed,
recent studies suggest that methylation of some ﬁeld-effect
genes is useful in detecting nearby prostate cancer.43,44
A mis-hit prostate biopsy with an AT methylation pattern
warrants additional examination for the presence of cancer in
the prostate gland.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.08.018.
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